Abstract: The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or an adjuvant for an antibiotic.

Abstract: The present disclosure provides a use of an osmolyte in the manufacture of a medicament treating protein aggregation related disorders, specifically provides a use of an osmolyte in the manufacture of a medicament treating TGFBI corneal dystrophies. The osmolyte is selected from a group consisting of betaine, raffmose, sarcosine, taurine and/or any pharmaceutically acceptable derivatives thereof.

Abstract: The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2,4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2,4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one a-lysine residue for an ?-lysine residue, and the modified peptides display antimicrobial activity.

Abstract: This disclosure provides methods of a method of treating a retinal angiogenic disease in a subject comprising administering an effective amount of an Angio-3 peptide.

Abstract: The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one ?-lysine residue for an ?-lysine residue, and the modified peptides display antimicrobial activity.

Abstract: The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.

Abstract: The present invention provides a polymer product and a method for preparing the polymer product comprising electrospinning from a dope solution comprising at least one polymer and at least one cross-linking agent to prepare and/or fabricate the polymer product. In certain embodiments, the cross-linking agent comprises at least one catecholamine or at least one polyphenol, wherein the method comprises (i) electrospinning the biocompatible polymer product using a dope solution comprising a polymer and at least one catecholamine or at least one polyphenol and (ii) exposing the polymer product to at least one gaseous alkaline reagent. The dope solutions and polymer products of the invention can further include antimicrobial agents, metal ions, and other substances.

Abstract: Disclosed are antimicrobial peptides. Also disclosed are methods of treating bacterial infection and fungal infection and a method of removing biofilm. Also disclosed is the use of these peptides.

Abstract: An isolated peptide tetramer includes the formula [(RGRKVVRR)2K]2KK and its derivatives thereof. The derivatives may include at least one amino acid substitution, at least one amino acid deletion, a rearrangement of the peptide monomer and/or at least one non-proteogenic amino acid modification in at least one peptide monomer. The isolated peptide tetramer and derivatives thereof have antimicrobial (antibacterial, antifungal and/or anti-protozoan) properties.